The Vasopressin V2 Receptor Antagonists: The Vaptans

Michael AB Naafs*

Naafs International Health Consultancy, Europe

*Corresponding author: Michael AB Naafs, Internist-endocrinologist with a long clinical career in internal medicine and endocrinology, Naafs International Health Consultancy, Europe, Email: naafs.healthconsultancy@gmail.com

Submission: March 26, 2018; Published: April 24, 2018

Abstract

In this mini-review the pathogenesis and pathophysiology of the new vasopressin antagonists are discussed. Indications, appropriate and inappropriate use of the vaptans are evaluated. The efficacy and safety of the vaptans has been well established. Costs are high and the vaptans are not cost-effective in the long-term treatment of autosomal dominant polycystic kidney disease (ADPKD) with a cost of U.S. $744,100 per equally adjusted life year (QALY) gained compared to standard care. This is seven times the standard willingness to pay threshold. A secondary analysis of the SALT trials reached no significant beneficial cost-benefit analysis for tolvaptan in the treatment of patients with the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). U.S. and European expert panels released different treatment guidelines. Solid endpoint studies on the increased mortality of hyponatremia are lacking.

Introduction

Vaptans (aquaretics) are novel V2 receptor antagonists that block vasopressin binding to collecting duct tubular cells of the kidney and increase free water excretion without significantly altering electrolyte excretion. These new therapeutic agents are effective in the treatment of euvoelemic and hypervolemic hyponatremia, the commonest electrolyte disorder in inpatients [1-3]. Furthermore, studies consistently find an excess morbidity and mortality in patients with hyponatremia compared to patients with normal plasma sodium concentrations.

The association has been reported in hospitalized patients [3,4], in intensive care units [5,6] and in apparently asymptomatic outpatients with much less severe forms of hyponatremia [7]. The association of hyponatremia with increased mortality maintains in numerous clinical settings including heart failure [8], cirrhosis [9], cancer [10], orthopaedic surgery [11], chronic kidney disease [12] and even in end stage kidney disease [13,14]. Guidelines of two expert panels are conflicting [15-17]. Traditional therapeutic approaches as fluid restriction, salt tablets, loop diuretics and normal saline have been limited efficacious [18,19]. Therefore, the development and availability of new drugs that antagonize the action of vasopressin and the pathogenesis of this disorder, is a most welcome addition to the therapeutic arsenal of hyponatremia. In this mini-review the pathogenesis and pathophysiology of AVP-V2 receptor antagonists are discussed as well as the use of the vaptans in clinical medicine.

Structure, Synthesis and Function of AVP

Arginine-vasopressin (AVP) and oxytocin (OT) are both neurohypophysial hormones and share a high sequence and structure homology. Four receptors exist in mammals, three for AVP and a unique receptor for OT, although AVP possesses a nanomolar affinity for all subtypes. AVP is also named the anti-diuretic hormone (ADH) due to its effect on the regulation of water balance. AVP is characterized by the presence of a disulfide bound between Cys1 and Cys6 (cysteine). This results in a peptide constituted of 6 amino-acid cyclic part and a COOH (carboxy) terminal alpha-animated three residue tail. AVP contains a basic amino-arginine at position 8 and phenylalanine at position 3. The presence of the glycynamide at the C-terminus is absolutely necessary for biological activity of the hormo.

AVP has multiple physiological functions, including body water regulation, control of blood pressure, platelet aggregation and release of coagulation factors, cell proliferation and effects on body temperature, insulin release, memory and social behavior. All these actions are mediated through activation of three specific membrane-bound receptors present at the surface of the target cells. On the basis of pharmacological and functional studies, these receptors have been classified as V1A, V8 and V2 subtypes [19]. There are various V1 and V2 receptors [19-24]. The selective abundance of the AVP-V2 receptor in the kidney determines the actions of AVP.
on a specific organ. Due to the immediate anti-diuresis (increased urinary osmolality, inversely proportional to urine production) observed in response to the administration of specific V2R agonists, such as L-desamino-8-D-arginine vasopressin (vasopressin, AVP, or desmopressin), it was previously thought that V2-VP receptors were exclusively present in the kidneys. Now it has been known that desmopressin in doses 10-30 times higher than used for anti-diuretic purposes increases circulating levels of coagulation factor 8 and von Willebrand factor (vWF) [25,26]. The hematomatous properties of desmopressin gradually changed the idea that V2AVP were exclusively present in the kidney. In patients with X-linked diabetes insipidus, who possess a mutation in the V2R gene (AVPR2), desmopressin failed to cause an increase in circulating vWF [27]. However, in patients with chronic renal failure, V2R agonist stimulation in high doses did raise plasma vWF even after bilateral nephrectomy [25]. These clinical observations strongly supported the existence of extra renal V2Rs. Later studies supported the existence of extra renal V2Rs and positively confirmed V2R effects in the endothelium [28-31].

Tight fluid homeostasis is critical not only at the whole body level but in most organs, tissues and physiological systems. Thus, it is not unexpected that the AVP-V2R complex also turns out to play a significant role in local fluid homeostasis, for instance by controlling the elimination and re-absorption of fluid in the inner ear through stimulation of V2Rs to mobilize AQP (aquaporins) water channels, likely in much the same way as occurs in the kidney [32]. The role of V2R in malignancy is less known. Many tumours produce and secrete AVP which has a mitogenic action on cellular growth. V2R is present in a wide panel of human tumour cell lines, including human breast cancer cells, cervical cancer and lung cancer and in corticotrophinomas [33-36]. An antibody-based proteomics showed staining for the AVPR2 gene in 29 of 75 cell types. This staining was most pronounced in the cytoplasm and membranes of the parathyroid. More moderate cytoplasmic staining was seen in the following cell types: the exocrine pancreas, non-keratinized squamous epithelial, smooth muscle, salivary glands, breast and Leydig cells. The physiologic role has to be determined, but other groups could not confirm these findings, possibly raising queries about the specificity of the antibodies used in these experiments [36].

Recently, it has been shown that female rats express significantly more V2R mRNA and protein in kidneys than male rats [37]. In humans the concept of a sex difference in renal sensitivity to desmopressin has been further supported by several studies in adult patients with nocturnia [38]. Autosomal dominant polycystic kidney disease is a ciliopathy characterized by renal cysts and altered fluid and electrolyte transport in the collecting duct. V2mRNAs are elevated compared with healthy subjects and the binding of AVP to V2Rs in the collecting duct increases cAMP and accelerates cyst growth by stimulating cell proliferation and Cl-dependent fluid secretion [39]. Deficiencies of any part of the renal AVP-V2R-AQP2 axis have profound clinical and pharmacological implications, being responsible for the development of central [40] or nephrogenic diabetes insipidus [41,42].

Use of V2R Antagonists

SIADH (syndrome of inappropriately antidiuretic hormone secretion) is one of the main indications for VRA use and malignancy is the commonest cause of SIADH [43]. Up to 15% of patients with SCLC (small cell lung cancer) develop SIADH [44]. Other indications are intracranial disorders, pulmonary disorders, medications, when chronic use is required, idiopathic, hyponatremia from heart failure, non severe hyponatremia and hyponatremia that is not amenable to correction with fluid restriction or other therapies (Table 1).

<table>
<thead>
<tr>
<th>Hyponatremia from syndrome of inappropriate antidiuretic hormone secretion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intracranial disorders.</td>
</tr>
<tr>
<td>Pulmonary disorders.</td>
</tr>
<tr>
<td>Medications, when chronic use is required.</td>
</tr>
<tr>
<td>Nausea or pain, when chronic and intractable.</td>
</tr>
<tr>
<td>Idiopathic.</td>
</tr>
<tr>
<td>Non-severe hyponatremia.</td>
</tr>
</tbody>
</table>

Hyponatremia that is not amenable to correction with fluid restriction or other therapies.

There is solid evidence supporting the efficacy of VRAs in cancer-associated SIADH. Salahdeen et al. [45] conducted a RCT in which the investigators randomized patients with cancer with non-hypovolemic hyponatremia to either placebo or tolvaptan. Patients in both groups were allowed to “drink to thirst”. The primary outcome was PNa (plasma natrium) correction by day 14. Secondary outcomes included length of hospital stay and change in Mini-Mental State Examination scores. The data safety monitoring board stopped the study after randomizing 30 patients when the primary endpoint was reached (94% in the tolvaptan group vs. 8% in the placebo group), which met study stopping for superiority. The secondary endpoints were statistically non-significant between the two groups.

Gralla et al. [46] performed a post hoc analysis of the SALT trials that analyzed 28 hyponatremic patients with SIADH and cancer. The most common causes of cancer were lung (29%), head and neck (25%), breast (11%) and renal cancer (11%). Patients in the tolvaptan group compared to placebo showed a highly significant improvement in PNa by day 14 (5 vs. -0.3mmol/l) and by day 30 (6, 9 vs. 1, 0mmol/l) [46]. The efficacy and safety of VRAs in the hyponatremia of heart failure and SIADH has been well established. The SALT-1 and SALT-2 were two identical RCTs: one in Europe and one in the America’s, which enrolled 448 patients with euvolemic or other therapies. Neutrophil stoppage of the study after randomizing 30 patients when the primary outcome was reached (94% in the tolvaptan group vs. 8% in the placebo group), which met study stopping for superiority. The secondary endpoints were statistically non-significant between the two groups.

Gralla et al. [46] performed a post hoc analysis of the SALT trials that analyzed 28 hyponatremic patients with SIADH and cancer. The most common causes of cancer were lung (29%), head and neck (25%), breast (11%) and renal cancer (11%). Patients in the tolvaptan group compared to placebo showed a highly significant improvement in PNa by day 14 (5 vs. 0.3mmol/l) and by day 30 (6, 9 vs. 1, 0mmol/l) [46]. The efficacy and safety of VRAs in the hyponatremia of heart failure and SIADH has been well established. The SALT-1 and SALT-2 were two identical RCTs: one in Europe and one in the America’s, which enrolled 448 patients with euvolemic and hyponatremia PNa<135mmol/l to tolvaptan or placebo and followed them for 30 days [47]. SIADH, heart failure and cirrhosis were the most common etiologies. These trials excluded patients with severe hyponatremia (presence of symptoms or PNa<120mmol/l). PNa at days 4 and 30 was significantly higher in the tolvaptan group compared to placebo showed a highly significant improvement in PNa by day 14 (5 vs. -0.3mmol/l) and by day 30 (6, 9 vs. 1, 0mmol/l) [46]. The efficacy and safety of VRAs in the hyponatremia of heart failure and SIADH has been well established. The SALT-1 and SALT-2 were two identical RCTs: one in Europe and one in the America’s, which enrolled 448 patients with euvolemic and hyponatremia PNa<135mmol/l to tolvaptan or placebo and followed them for 30 days [47]. SIADH, heart failure and cirrhosis were the most common etiologies. These trials excluded patients with severe hyponatremia (presence of symptoms or PNa<120mmol/l). PNa at days 4 and 30 was significantly higher in the tolvaptan group compared to placebo showed a highly significant improvement in PNa by day 14 (5 vs. -0.3mmol/l) and by day 30 (6, 9 vs. 1, 0mmol/l) [46]. The efficacy and safety of VRAs in the hyponatremia of heart failure and SIADH has been well established. The SALT-1 and SALT-2 were two identical RCTs: one in Europe and one in the America’s, which enrolled 448 patients with euvolemic and hyponatremia PNa<135mmol/l to tolvaptan or placebo and followed them for 30 days [47]. SIADH, heart failure and cirrhosis were the most common etiologies. These trials excluded patients with severe hyponatremia (presence of symptoms or PNa<120mmol/l). PNa at days 4 and 30 was significantly higher in the tolvaptan group compared to placebo showed a highly significant improvement in PNa by day 14 (5 vs. -0.3mmol/l) and by day 30 (6, 9 vs. 1, 0mmol/l) [46]. The efficacy and safety of VRAs in the hyponatremia of heart failure and SIADH has been well established. The SALT-1 and SALT-2 were two identical RCTs: one in Europe and one in the America’s, which enrolled 448 patients with euvolemic and hyponatremia PNa<135mmol/l to tolvaptan or placebo and followed them for 30 days [47]. SIADH, heart failure and cirrhosis were the most common etiologies. These trials excluded patients with severe hyponatremia (presence of symptoms or PNa<120mmol/l). PNa at days 4 and 30 was significantly higher in the tolvaptan group compared to placebo showed a highly significant improvement in PNa by day 14 (5 vs. -0.3mmol/l) and by day 30 (6, 9 vs. 1, 0mmol/l) [46]. The efficacy and safety of VRAs in the hyponatremia of heart failure and SIADH has been well established. The SALT-1 and SALT-2 were two identical RCTs: one in Europe and one in the America’s, which enrolled 448 patients with euvolemic and hyponatremia PNa<135mmol/l to tolvaptan or placebo and followed them for 30 days [47]. SIADH, heart failure and cirrhosis were the most common etiologies. These trials excluded patients with severe hyponatremia (presence of symptoms or PNa<120mmol/l).
of them. Adverse events occurred at similar rates in the placebo and the experimental groups in the SALT trials. The majority of adverse events were related to the aquaretic properties of tolvaptan including hypotension and increased thirst and urination. Overcorrection of hyponatremia occurred only in 1, 8% of patients in the SALT trials.

The SALTWATER STUDY constituted the follow up of the salt trials enrolling 111 patients and followed them for a median of 1, 9 years. All patients received tolvaptan that was titrated up to a normal PNa. Fifty-seven percent of patients achieved normal PNa which was maintained during the study. Tolvaptan has been shown to have an overall acceptable safety profile in these two studies. Only six patients in the saltwater study discontinued the study drug due to the aquaretic adverse events of tolvaptan described above [48].

Zeltser et al. [48] randomized 84 patients with euvolemic or hypervolemic hyponatremia with PNa ranging from 115 to 130 mmol/l to two different doses of conivaptan (40 and 80mg) or placebo for 4 days. SIADH and heart failure were the most common causes of hyponatremia in this population [49]. Conivaptan, regardless of the dose, was associated with a significant increase in PNa. No difference in PNa was found between conivaptan doses. The rate of adverse events in both groups was similar. Nevertheless conivaptan was associated with a higher rate incidence of phlebitis and other infusion site reactions especially when the 80mg dose was used. Other adverse events attributed to conivaptan were hypotension and renal dysfunction. None of these led to discontinuation of the drug. Overcorrection of hyponatremia occurred in 7% of patients on conivaptan in this study.

Five meta-analyses have been published establishing the efficacy of VRAs in the treatment of hyponatremia [50]. Rosen Zvi et al. [51] evaluated 15 studies produced from 1999-2009 assessing the short-term effects of all VRAs combined in the treatment of euvolemic or hypervolemic hyponatremia involving 1125 patients. VRAs were associated with a greater early response rate than controls (RR=3, 15; 95% CI: 2.27-4.37) but with significant heterogeneity (I$^2$(I quadrate)=67%). A risk of rapid PNa correction was also found in 12 studies of this meta-analysis with a RR=2.56 (95% CI: 1.45-4.53) [53].

Zhang et al. [53] conducted a meta-analysis of 18 RCTs published between 2003 and 2014 that examined the efficacy of all VRAs in the treatment of euvolemic and hypervolemic hyponatremia involving 1094 patients. VRAs were associated with a significant rise in PNa of 3, 9mmol/l at day 1 (95% CI: 2.7-3.8; p<0.001) without significant heterogeneity (I$^2$(I quadrate)=0%, p=0.51). This meta-analysis also found an increase of rapid PNa correction with an OR of 3, 0 (p<0.001) in nine trials [52].

Li et al. [54] carried out the analysis of 11 studies published between 2008 and 2016 that examined the efficacy of tolvaptan in the treatment of hyponatremia covering 5209 patients. Nine studies reported the changes in PNa after tolvaptan therapy and significant heterogeneity was observed across these studies (I$^2$(I quadrate)=76%; p<0.001). Therefore, a random effect model was used. The use of tolvaptan was found to be associated with an increase in PNa of 3.99mmol/l (95% CI: 2.80-5.19; p=0.001). Publication bias was not found. The use of tolvaptan was also found to be associated with a rapid PNa correction (RR=8.43; 95% CI: 1.06-66.69; p=0.04) in two trials [54].

Bhandari et al. [55] performed a meta-analysis of 18 trials published between 2013 and 2014 that examined the effectiveness of VRAs in hyponatremia and included a total of 3408 patients in their analysis. The analysis suggests that patients randomized to a VRA (except conivaptan) are significantly more likely to normalize PNa or increase it by more than 5mmol/l with tolvaptan having the largest effect (RR=3.3; 95% CI: 1.97-5.54). However, pooled analysis of tolvaptan trials showed a statistically significant risk of rapid PNa correction (RR=0.85; 95% CI: 1.27-76.35; p=0.03) with uncertain effect size given low numbers of events in each individual trial [55].

The efficacy of tolvaptan is also supported by the analysis of the largest hyponatremia registry to this date with over 3000 patients describing therapeutic practice patterns regarding hyponatremia in the U.S. and Europe [17,56]. In this registry, the rise in PNa during the first 24 hours was greater with tolvaptan compared to other traditional therapies. Similar results were observed in the analysis of a registry of cancer patients with euvolemic hyponatremia [57].

**Inappropriate Use of Vras**

### Table 2: VRA

<table>
<thead>
<tr>
<th>Contraindicated.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypovolemia</td>
</tr>
<tr>
<td>Gastrointestinal losses: vomiting, diarrhea and bleeding</td>
</tr>
<tr>
<td>Skin losses: burns and excessive sweating</td>
</tr>
<tr>
<td>Third spacing: acute pancreatitis and small bowel obstruction</td>
</tr>
<tr>
<td>Renal losses: diuretic use, aldosterone deficiency, cerebral salt wasting syndrome and salt wasting</td>
</tr>
</tbody>
</table>
The use of VRAs is considered inappropriate in a number of settings (Table 2). VRAs are contraindicated in hyponatremia due to hypovolemia as its use may exacerbate hypotension [16]. Hypovolemia can be caused by gastrointestinal losses such as vomiting and diarrhea and bleeding and by skin losses such as excessive sweating and burns. Third spacing in the case of acute pancreatitis and small bowel obstruction also has been reported. Renal losses due to use of diuretics and salt wasting nephropathy are other causes of hypovolemic hyponatremia as aldosterone deficiency and the cerebral wasting syndrome (CSWS) are mentioned. CSWS shares many clinical features of SIADH [58].

Hyponatremia in CSWS appears in the context of intracranial pathology, typically subarachnoid hemorrhage, where either an impaired sympathetic input or an unidentified brain peptide associated with the intracranial disorder causes sodium wasting. As in SIADH, patients with CSWS have also a hypotonic hyponatremia associated with high urine osmolality and high urine sodium but they are actually hypovolemic from sodium wasting. CSWS seems to be a rare entity as most cases of hyponatremia in the context of subarachnoid hemorrhage are either due to SIADH or cortisol deficiency [59,60].

Concerns for liver damage associated with VRAs appeared in the TEMPO 3:4 trial studying the efficacy and safety of tolvaptan to slow down the progression of autosomal dominant polycystic kidney disease (ADPKD) [61]. No elevation of liver function tests was observed in the SALT and SALTWATER trials. It is important to point out that the tolvaptan doses used in the TEMPO 3:4 trials were much higher than the doses commonly used to treat hyponatremia. A post hoc analysis study demonstrated that these events are rare [62]. Nevertheless the FDA issued a drug safety communication restricting the use of tolvaptan to 30 days and avoiding its use in patients with underlying liver disease [63]. Conivaptan a dual V1A/V2 receptor antagonist effect scan trigger splanchnic vasodilatation and subsequent hypotension, hepatorenal syndrome and variceal bleeding [64].

Vaptans and Screening for ADPKD

The prevalence of ADPKD is 3 to 4/10,000 in the general population [65]. It is the most common inherited kidney disease. ADPKD is due to gene mutations, mostly in the PKD1 or PKD2 gene [66]. These mutations result in numerous cysts in both kidneys. Seventy percent of patients reach end-stage renal disease (ESRD) at the median age of 58 years [67]. Well known complications are pain, bleeding and infections of the cysts [66]. Renal cysts are accompanied frequently by liver cysts [66]. Renal failure results in cardiovascular problems as hypertension and aneurysms [66].

Until now the treatment consisted of blood pressure control, salt restriction and life style recommendations in the lack of therapeutic options to prevent progressive renal failure [68]. Rigid blood pressure control is not recommended because the rate of renal function decline is not altered, despite a small inhibitory effect on renal cyst growth [69]. Tolvaptan has shown to modulate and inhibit cyst cell proliferation [61]. Tolvaptan delays renal function decline during treatment 5 years long [61,70]. This effect is independent of age, severity of renal failure and duration of treatment. Tolvaptan delays renal function decline with 26% a year. This means 4 years of tolvaptan therapy results in starting dialysis one year later [61]. The most common adverse events are polyuria, thirst and nocturia.

Screening for ADPKD is possible by ultrasound at a very young age [66]. The use of DNA analysis as a screening tool is limited because it is time consuming, expensive and complex. Until now screening for ADPKD was not recommended because a causal therapy was not available. Tolvaptan has changed this
Outcomes in 57 adult patients age 50 and older with chronic and study aimed to investigate the effects of tolvaptan on hyponatremia insight study was a multicenter randomized double-blind pilot trials and in the SALT-1 trial but not in the SALT-2 trial [47]. The delay of 26% in renal function decline yearly with tolvaptan is significantly improved in the combined analysis of both SALT patients stopped tolvaptan for reasons of adverse events [61,70].

Supporters recommend ADPKD screening for young adult family members of ADPKD patients, especially in the US [71]. They also argue that ADPKD screening offers the possibility of IVF (in vitro fertilization) genetic-pre-implantation procedures when one of both partners has ADPKD. Patients with ADPKD have an increased risk of cerebral aneurysms [61]. Therefore a family history of subarachnoid bleedings at young age could be a reason for screening on cerebral aneurysms eg. once in 5-10 years, starting at the age of 30 [61]. Estrogens and progestagens can increase growth of liver cysts. Oral contraceptives are not recommended for women with ADPKD [68]. In the TEMPO 3:4 study only 8.3% of patients stopped tolvaptan for reasons of adverse events [61,70]. The delay of 26% in renal function decline yearly with tolvaptan is comparable to ACE (angiotensin converting enzyme) inhibition of the development of diabetic nephropathy [72].

Screening for ADPKD has 3 Possible Results

1. ADPKD is not present.
2. ADPKD is present but is not of the rapidly progressive type.
3. ADPKD presents in its rapidly progressive manifestation.

This means:

1. Half of screened young adults has no polycystic kidney disease and can be reassured.
2. One quarter has no rapidly progressive ADPKD which is partly reassuring.
3. One quarter has rapidly progressive ADPKD amenable to therapy with V2R antagonists.

It is concluded that the balance favours ADPKD screening in young adult ADPKD family members or at least one screening visit.

Effects of VRAs on Morbidity

Recent evidence suggests that mild or asymptomatic hyponatremia is associated with increased risk of morbidity outcomes such as neurocognitive deficits and gait abnormalities [7]. The mental component of the SF-12 survey of general health was significantly improved in the combined analysis of both SALT trials and in the SALT-1 trial but not in the SALT-2 trial [47]. The insight study was a multicenter randomized double-blind pilot study aimed to investigate the effects of tolvaptan on hyponatremia outcomes in 57 adult patients age 50 and older with chronic and apparently asymptomatic hyponatremia (PNa120-135mmol/l) [73]. The primary endpoint was change neurocognitive composite scores of speed domains (reaction time, psychomotor speed and processing speed). Mean base line scores were found to be more than 1 SD lower compared to age matched normal controls. Use of tolvaptan was associated with a statistically significant increase in PNa (from 129 to 136mEq/L) compared to placebo (from 130 to132mEq/L; p<0.001). There was no difference in the primary outcome. However, tolvaptan use was associated with a statistically significant improvement of score in the psychomotor speed domain (treatment effect, 0.27; 95% CI: 0.04-0.51; p=0.03)

Effects of VRAs on Mortality

The ACTIV in CHF trial randomized 319 hospitalized patients with heart failure ejection fraction of less than 40% with refractory congestive symptomatology to tolvaptan or placebo. Despite a significant weight loss associated with tolvaptan rates of worsening heart failure were not different than placebo [74]. Post hoc analysis of this trial showed decreased mortality at 60 days associated with improvement of PNa with tolvaptan use [75].

Subsequently, the Everest outcome trial randomized 4133 hospitalized patients with heart failure to tolvaptan or placebo [76]. Primary outcomes were all cause mortality and a combined endpoint of cardiovascular mortality or subsequent hospitalization for worsening heart failure. Only 11.4% of patients had hyponatremia at baseline in this trial. There were no significant differences in the primary outcomes between groups. A subgroup analysis of this trial showed that tolvaptan was associated with a significant reduction in cardiovascular morbidity and mortality after discharge [77].

Costs of Tolvaptan

Tolvaptan is used infrequently among patients with heart failure and hyponatremia and is used among sicker patients [78]. The Premier hospital data base was analyzed to assess the utilization of tolvaptan to estimate tolvaptan costs of managing patients with heart failure (HF) and hyponatremia (HN) and the budget impact of tolvaptan use. Tolvaptan was used in 4.96% of inpatient visits of tolvaptan use. Tolvaptan was used in 4.96% of inpatient visits of tolvaptan to estimate tolvaptan costs of managing patients with heart failure were not different than placebo [74]. Post hoc analysis of this trial showed decreased mortality at 60 days associated with improvement of PNa with tolvaptan use [75].

Data on the cost effectiveness of tolvaptan are very limited [79]. Erickson et al. [80] developed a decision-analytic model to study the cost effectiveness of tolvaptan for slowing the progression of ADPKD. They compared a case in which patients with ADPKD receive tolvaptan for life, assuming its clinical benefit persists for 30.46%. Additionally, utilization increased by length of stay, which can serve as a proxy to disease severity, Tolvaptan costs accounted for 0.3% of total hospitalization related costs for patients with HF and HN and the budget impact was $52.42 per visit [78].

Data on the cost effectiveness of tolvaptan are very limited [79]. Erickson et al. [80] developed a decision-analytic model to study the cost effectiveness of tolvaptan for slowing the progression of ADPKD. They compared a case in which patients with ADPKD receive tolvaptan for life, assuming its clinical benefit persists for life until their death, the development of ESRD (end stage renal disease) or liver complications to a case in which these patients received standard care. Measured outcomes included median age
at onset of ESRD, life expectancy and discontinued quality-adjusted life years (QALYs). Results showed that tolvaptan therapy in 40-year-old men and women with ADPKD with an eGFR of 80 ml/min/1.73 square meter would prolong the median age of ESRD onset by 6, 3 years in women and 6, 8 years in men, increase life expectancy by 2, 8 years in women and 2, 3 years in men and yield an increase of 1, 2 discontinued QALYs in women and 1, 1 discontinued QALYs in men. This finding suggests a remarkable health benefit if tolvaptan effectiveness can actually be sustained. It would delay RRT (renal replacement therapy) and its high cost, loss of QOL (quality of life) and death associated with ESRD. The benefits would come at a very high cost U.S. $5.760 per month and U.S. $744, 100 per QALY gained compared to standard care. This is seven times the standard willingness-to-pay WTP threshold, which ranges from U.S.$50,000-U.S. 100.000 per QALY gained [81]. These results clearly showed that tolvaptan is not cost effective.

Dasta et al. [82] performed a study to evaluate the potential costs savings associated with tolvaptan usage in SIADH based on the SALT trials. Use of tolvaptan was associated with a reduced hospital stay and an estimated mean hospital cost reduction of $694 per admission in the United States [82].

Cyr et al. [83] conducted a secondary analysis of the SALT trials and showed that hyponatremic patients who received tolvaptan had a hospital stay that was 1, 72 days shorter compared to placebo but this reached not statistical significance [83]. Lee et al. [84] developed a decision-analytic model using the Korean National Health Insurance database to measure the financial impact of tolvaptan compared with placebo in patients with euvoemlic and hypovolemic hyponatremia during a 1 month treatment period. The analysis revealed that tolvaptan was more efficacious with less associated costs in patients with marked hyponatremia [84].

Jamokeeah et al. [85] performed a cost-utility analysis using a discrete event simulation model to predict the progression of patients with hyponatremia who have failed fluid restriction (or were not suitable to fluid restriction) and were therefore treated with tolvaptan or no active treatment through inpatient admissions over a 30 day period in Sweden. Tolvaptan was associated with reduced costs and increased quality-adjusted life years compared with no active treatment strategy [85].

Conclusion

Vaptans are novel V2 receptor antagonists (VRAs) that are effective in the treatment of euvoemlic and hypovolemic hyponatremia. The efficacy and safety of VRAs in the hyponatremia of heart failure and the syndrome of inappropriate anti-diuretic hormone secretion (SIADH) has been well established. Screening for ADPKD (autosomal dominant polycystic kidney disease) of young adult ADPKD family members is favoured in the U.S. but not yet in Europe. Hard data on the impact of VRAs on solid endpoints such as cardiovascular events, hospitalizations and death are lacking. Tolvaptan is not cost effective in the life-long treatment of ADPKD patients with a cost of U.S. $744,100 per quality adjusted life-year (QALY) gained compared to standard care. This is seven times the standard willingness-to-pay threshold. More solid end point studies should be performed to ascertain whether the correction of hyponatremia make disappear the increased mortality of this electrolyte disorder.

References


How to cite this article: Michael A N. The Vasopressin V2 Receptor Antagonists: The Vaptans. Glob J Endocrinol Metab. 2(1). GJEM.000529.2018. DOI: 10.31031/GJEM.2018.02.000529


63. US Food and Drug Administration (2013) FDA Drug Safety Communication: FDA Limits Duration and Usage of Samsca (Tolvaptan) due to Possible Liver Injury Leading to Organ Transplant or Death.


